Cargando…

S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis

BACKGROUND: Seronegative joint diseases are characterized by a lack of well-defined biomarkers since autoantibodies are not elevated. Calprotectin (S100A8/A9) is a damage-associated molecular pattern (DAMP) which is released by activated phagocytes, and high levels are found in seronegative arthriti...

Descripción completa

Detalles Bibliográficos
Autores principales: Geven, Edwin J. W., van den Bosch, Martijn H. J., Di Ceglie, Irene, Ascone, Giuliana, Abdollahi-Roodsaz, Shahla, Sloetjes, Annet W., Hermann, Sven, Schäfers, Michael, van de Loo, Fons A. J., van der Kraan, Peter M., Koenders, Marije I., Foell, Dirk, Roth, Johannes, Vogl, Thomas, van Lent, Peter L. E. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078998/
https://www.ncbi.nlm.nih.gov/pubmed/27776554
http://dx.doi.org/10.1186/s13075-016-1121-z
_version_ 1782462493936844800
author Geven, Edwin J. W.
van den Bosch, Martijn H. J.
Di Ceglie, Irene
Ascone, Giuliana
Abdollahi-Roodsaz, Shahla
Sloetjes, Annet W.
Hermann, Sven
Schäfers, Michael
van de Loo, Fons A. J.
van der Kraan, Peter M.
Koenders, Marije I.
Foell, Dirk
Roth, Johannes
Vogl, Thomas
van Lent, Peter L. E. M.
author_facet Geven, Edwin J. W.
van den Bosch, Martijn H. J.
Di Ceglie, Irene
Ascone, Giuliana
Abdollahi-Roodsaz, Shahla
Sloetjes, Annet W.
Hermann, Sven
Schäfers, Michael
van de Loo, Fons A. J.
van der Kraan, Peter M.
Koenders, Marije I.
Foell, Dirk
Roth, Johannes
Vogl, Thomas
van Lent, Peter L. E. M.
author_sort Geven, Edwin J. W.
collection PubMed
description BACKGROUND: Seronegative joint diseases are characterized by a lack of well-defined biomarkers since autoantibodies are not elevated. Calprotectin (S100A8/A9) is a damage-associated molecular pattern (DAMP) which is released by activated phagocytes, and high levels are found in seronegative arthritides. In this study, we investigated the biomarker potential of systemic and local levels of these S100 proteins to assess joint inflammation and joint destruction in an experimental model for seronegative arthritis. METHODS: Serum levels of S100A8/A9 and various cytokines were monitored during disease development in interleukin-1 receptor antagonist (IL-1Ra)(–/–) mice using ELISA and multiplex bead-based immunoassay, and were correlated to macroscopic and microscopic parameters for joint inflammation, bone erosion, and cartilage damage. Local expression of S100A8 and S100A9 and matrix metalloproteinase (MMP)-mediated cartilage damage in the ankle joints were investigated by immunohistochemistry. In addition, local S100A8 and activated MMPs were monitored in vivo by optical imaging using anti-S100A8-Cy7 and AF489-Cy5.5, a specific tracer for activated MMPs. RESULTS: Serum levels of S100A8/A9 were significantly increased in IL-1Ra(–/–) mice and correlated with macroscopic joint swelling and histological inflammation, while serum levels of pro-inflammatory cytokines did not correlate with joint swelling. In addition, early serum S100A8/A9 levels were prognostic for disease outcome at a later stage. The increased serum S100A8/A9 levels were reflected by an increased expression of S100A8 and S100A9 within the ankle joint, as visualized by molecular imaging. Next to inflammatory processes, serum S100A8/A9 also correlated with histological parameters for bone erosion and cartilage damage. In addition, arthritic IL-1Ra(–/–) mice with increased synovial S100A8 and S100A9 expression showed increased cartilage damage that coincided with MMP-mediated neoepitope expression and in vivo imaging of activated MMPs. CONCLUSIONS: Expression of S100A8 and S100A9 in IL-1Ra(–/–) mice strongly correlates with synovial inflammation, bone erosion, and cartilage damage, underlining the potential of S100A8/A9 as a systemic and local biomarker in seronegative arthritis not only for assessing inflammation but also for assessing severity of inflammatory joint destruction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1121-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5078998
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50789982016-10-31 S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis Geven, Edwin J. W. van den Bosch, Martijn H. J. Di Ceglie, Irene Ascone, Giuliana Abdollahi-Roodsaz, Shahla Sloetjes, Annet W. Hermann, Sven Schäfers, Michael van de Loo, Fons A. J. van der Kraan, Peter M. Koenders, Marije I. Foell, Dirk Roth, Johannes Vogl, Thomas van Lent, Peter L. E. M. Arthritis Res Ther Research Article BACKGROUND: Seronegative joint diseases are characterized by a lack of well-defined biomarkers since autoantibodies are not elevated. Calprotectin (S100A8/A9) is a damage-associated molecular pattern (DAMP) which is released by activated phagocytes, and high levels are found in seronegative arthritides. In this study, we investigated the biomarker potential of systemic and local levels of these S100 proteins to assess joint inflammation and joint destruction in an experimental model for seronegative arthritis. METHODS: Serum levels of S100A8/A9 and various cytokines were monitored during disease development in interleukin-1 receptor antagonist (IL-1Ra)(–/–) mice using ELISA and multiplex bead-based immunoassay, and were correlated to macroscopic and microscopic parameters for joint inflammation, bone erosion, and cartilage damage. Local expression of S100A8 and S100A9 and matrix metalloproteinase (MMP)-mediated cartilage damage in the ankle joints were investigated by immunohistochemistry. In addition, local S100A8 and activated MMPs were monitored in vivo by optical imaging using anti-S100A8-Cy7 and AF489-Cy5.5, a specific tracer for activated MMPs. RESULTS: Serum levels of S100A8/A9 were significantly increased in IL-1Ra(–/–) mice and correlated with macroscopic joint swelling and histological inflammation, while serum levels of pro-inflammatory cytokines did not correlate with joint swelling. In addition, early serum S100A8/A9 levels were prognostic for disease outcome at a later stage. The increased serum S100A8/A9 levels were reflected by an increased expression of S100A8 and S100A9 within the ankle joint, as visualized by molecular imaging. Next to inflammatory processes, serum S100A8/A9 also correlated with histological parameters for bone erosion and cartilage damage. In addition, arthritic IL-1Ra(–/–) mice with increased synovial S100A8 and S100A9 expression showed increased cartilage damage that coincided with MMP-mediated neoepitope expression and in vivo imaging of activated MMPs. CONCLUSIONS: Expression of S100A8 and S100A9 in IL-1Ra(–/–) mice strongly correlates with synovial inflammation, bone erosion, and cartilage damage, underlining the potential of S100A8/A9 as a systemic and local biomarker in seronegative arthritis not only for assessing inflammation but also for assessing severity of inflammatory joint destruction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1121-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-24 2016 /pmc/articles/PMC5078998/ /pubmed/27776554 http://dx.doi.org/10.1186/s13075-016-1121-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Geven, Edwin J. W.
van den Bosch, Martijn H. J.
Di Ceglie, Irene
Ascone, Giuliana
Abdollahi-Roodsaz, Shahla
Sloetjes, Annet W.
Hermann, Sven
Schäfers, Michael
van de Loo, Fons A. J.
van der Kraan, Peter M.
Koenders, Marije I.
Foell, Dirk
Roth, Johannes
Vogl, Thomas
van Lent, Peter L. E. M.
S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis
title S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis
title_full S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis
title_fullStr S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis
title_full_unstemmed S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis
title_short S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis
title_sort s100a8/a9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078998/
https://www.ncbi.nlm.nih.gov/pubmed/27776554
http://dx.doi.org/10.1186/s13075-016-1121-z
work_keys_str_mv AT gevenedwinjw s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT vandenboschmartijnhj s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT diceglieirene s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT asconegiuliana s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT abdollahiroodsazshahla s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT sloetjesannetw s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT hermannsven s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT schafersmichael s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT vandeloofonsaj s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT vanderkraanpeterm s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT koendersmarijei s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT foelldirk s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT rothjohannes s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT voglthomas s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis
AT vanlentpeterlem s100a8a9apotentserumandmolecularimagingbiomarkerforsynovialinflammationandjointdestructioninseronegativeexperimentalarthritis